- Home
- CHRS vs TCI Comparison
CHRS vs TCI Comparison
Compare CHRS & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | TCI |
|---|---|---|
| Founded | 2010 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.8M | 308.7M |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CHRS | TCI |
|---|---|---|
| Price | $1.58 | $37.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 1.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | 135.29 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $49,060,000.00 |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | N/A |
| P/E Ratio | ★ N/A | $1,783.50 |
| Revenue Growth | N/A | ★ 4.23 |
| 52 Week Low | $0.72 | $31.48 |
| 52 Week High | $2.62 | $59.65 |
Technical Indicators
Market Signals| Indicator | CHRS | TCI |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 47.33 |
| Support Level | $1.55 | $34.20 |
| Resistance Level | $1.75 | $38.38 |
| Average True Range (ATR) | 0.08 | 1.07 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 43.31 | 16.95 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.